BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11

• Press Releases

  U.S. Patient with Advanced Lung Cancer Stabilized by Novel Immunotherapy Treatment in China

  March 9, 2026

   · 

  1 min read
• Press Releases

  Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

  March 9, 2026

   · 

  9 min read
• Press Releases

  Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)

  March 9, 2026

   · 

  9 min read
• Press Releases

  Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  March 9, 2026

   · 

  1 min read
• Press Releases

  Lobe Sciences Announces Appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial Officer

  March 9, 2026

   · 

  7 min read
• Press Releases

  [Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer

  March 9, 2026

   · 

  14 min read
• Press Releases

  AGAMREE® (vamorolone) Data Presented at MDA 2026 Confirm Comparable Long-Term Effectiveness for up to 8 Years of Treatment, with Clinically Meaningful Safety Advantages in Duchenne Muscular Dystrophy

  March 9, 2026

   · 

  8 min read
• Press Releases

  Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma

  March 9, 2026

   · 

  8 min read
• Press Releases

  Egetis Receives Notice of Allowance for MCT8 Deficiency Composition Patent in the U.S.

  March 9, 2026

   · 

  4 min read
• Press Releases

  Leads Biolabs’ Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China’s High-Incidence Cancer

  March 9, 2026

   · 

  6 min read